Home' Australian Pharmacist : Australian Pharmacist November 2015 Contents Australian Pharmacist November 2015 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD & PI program.
The CPD section is recognised under the PSA
CPD & PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer.
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4 out
of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD credits.
PSA members can answer online at www.psa.org.au.
• Login to submit your answers online. If you
do not have member access details, you can
request them via a link from the login page.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
Submit your answers online before
1 January 2018 at www.psa.org.au and
receive automatic feedback.
1. Mrs Rose is an 84-year-old woman
with moderate dementia. She has
recently started to refuse a number
of medicines that she has taken for
several years when her husband
attempts to administer them to her.
Which ONE of the following is the
MOST appropriate initial strategy to
resolve this issue?
a) Explain in detail to her the benefits that
each medicine provides.
b) Identify the potential reasons for her
c) Commence a low dose of risperidone.
d) Cease all medicines that are
2. Which ONE of the following
strategies is MOST consistent with
the concept of deprescribing?
a) Discontinuing all medicines with high
risk of adverse effects.
b) Ceasing all medicines that do not
provide symptomatic benefit.
c) Discontinuing medicines with an
unfavourable risk-benefit ratio.
d) Ensure that every medical condition
is treated strictly according to current
3. Which ONE of the following
statements regarding the secondary
prevention of myocardial infarction
(MI) in older people is the LEAST
a) There is no evidence that
discontinuation of aspirin post-MI is
associated with an increased risk of
b) Most of the benefits resulting from
beta-blockers administered post-MI
are realised within the first three years
c) The risk of poor outcomes associated
with hypoglycaemia generally
outweighs the benefit of stringent
blood glucose control (HbA1c
d) Statins are generally as beneficial for
secondary prevention of MI in older
people as in younger people.
4. Considering the risk-benefit ratio
and in light of no adverse effects
to the patient, in which ONE of the
following scenarios is the strategy
of deprescribing the medicine cited
LEAST likely to be of value?
a) A 96-year-old woman with a 15-year
history of Alzheimer’s disease whose
only medicine is alendronate for primary
prevention of osteoporosis.
b) A 68-year-old woman with newly
diagnosed type 2 diabetes whose
only medicine is rosuvastatin for
c) A 62-year-old man with metastatic small
cell lung cancer who is taking ramipril
d) A 74-year-old man with no significant
medical history whose only medicine is
5. Which ONE of the following
statements regarding urinary
incontinence in people with
dementia is the MOST appropriate?
a) Bladder training is an effective
management strategy in advanced
b) Prompted voiding requires minimal
commitment from carers to be effective.
c) Mirabegron has been shown to be safe
and effective in people with dementia.
d) Multi-factorial strategies are generally
more effective than single interventions.
10. Rodríguez LA, Cea-Soriano L, Martín-Merino E, et al.
Discontinuation of low dose aspirin and risk of myocardial
infarction: case-control study in UK primary care. Br Med J
11. Heart Protection Study Collaborative Group. MRC/BHF
Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: a randomised
placebo-controlled trial. Lancet 2002;360(9326):7–22.
12. Miettinen TA1, Pyörälä K, Olsson AG, et al. Cholesterol-
lowering therapy in women and elderly patients with
myocardial infarction or angina pectoris: findings from the
Scandinavian Simvastatin Survival Study (4S). Circulation
13. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/
AHA guideline on the treatment of blood cholesterol to
reduce atherosclerotic cardiovascular risk in adults: a report
of the American College of Cardiology/American Heart
Association task force on practice guidelines. Circulation
2014;129(25 Suppl 2):S1–45.
14. Nowson CA, McGrath JJ, Ebeling PR, et al. Vitamin D and
health in adults in Australia and New Zealand: a position
statement. Med J Aust 2012;196(11):686–7 .
15. Bolland MJ, Grey A, Gamble GD, et al. The effect of vitamin D
supplementation on skeletal, vascular, or cancer outcomes:
a trial sequential meta-analysis. Lancet Diabetes Endocrinol
16. The Royal Australian College of General Practitioners and
Diabetes Australia. General practice management of type
2 diabetes – 2014–15. Melbourne, Victoria: RACGP and
DA;2014. At: www.racgp.org.au/your-practice/guidelines/
17. Orme S, Morris V, Gibson W, et al. Managing urinary
incontinence in patients with dementia: pharmacological
treatment options and considerations. Drugs Aging
18. de Codt A, Grotz C, Degaute MF, et al. Management of
demented patients with urinary incontinence: a case study.
Clin Neuropsychol 2015;29(5):707–22 .
19. Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational
β3 adreno-receptor agonists for the management of the
overactive bladder syndrome. Expert Opin Investig Drugs
Links Archive Australian Pharmacist October 2015 Australian Pharmacist December 2015 Navigation Previous Page Next Page